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ABSTRACT 
Background: Left ventricular ejection fraction (LVEF) is the preferred clinical marker of 
myocardial function and a predictor of recurrent cardiovascular events following acute 
myocardial infarction (AMI). However, LVEF is mainly determined by global systolic function 
while not adequately reflecting other components of cardiac contractility and has, therefore, 
major limitations as a standalone prognostic marker for post-infarction outcome. Measurement 
of left ventricular myocardial dyssynchrony may improve risk assessment after AMI, which was 
subject of the present study.  
Methods: A total of 1082 consecutive patients with AMI (STEMI: n=762; NSTEMI: n=320) 
undergoing cardiac magnetic resonance (CMR) imaging in median 3 days after infarction were 
included in this multicenter study. Circumferential and radial uniformity ratio estimates (CURE 
and RURE) were derived from CMR feature-tracking as markers of dyssynchrony (values 
between 0 and 1 with 1 reflecting perfect synchrony). The clinical study endpoint was the rate 
of major adverse cardiac events (MACE) at 12 months, consisting of all-cause death, re-
infarction, and new congestive heart failure.  
Results: Patients with MACE had significantly impaired dyssynchrony estimates (p<0.001 for 
CURE and RURE compared to patients without events). Stratification according to median 
CURE (0.84) and RURE (0.75) resulted in significantly increased 12-month MACE rates in AMI 
patients with uniformity ratio estimates below the median (p=0.001 in log-rank testing for all). 
In post-infarction patients with a LVEF >35% (n=959), CURE was identified as an independent 
predictor of outcome even after adjustment for established prognostic markers (p=0.011 in 
stepwise multivariate Cox regression analysis) while LVEF was not associated with adverse 
events in this subgroup of AMI patients. 
Conclusions: Left ventricular myocardial dyssynchrony is a novel marker for optimized risk 
assessment after AMI and provides incremental prognostic information particularly in patients 
with preserved or only moderately reduced LVEF. 
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ABBREVIATIONS 
AMI   Acute myocardial infarction 
b-SSFP  Balanced steady-state free precession 
CI   Confidence interval 
CMR   Cardiac magnetic resonance 
CMR-FT  Cardiac magnetic resonance myocardial feature tracking 
CURE   Circumferential uniformity ratio estimate 
HR   Hazard ratio 
IQR   Interquartile range 
LV   Left ventricular 
LVEF   Left ventricular ejection fraction 
MACE   Major adverse cardiac events 
NSTEMI  Non-ST-segment elevation myocardial infarction 
RURE   Radial uniformity ratio estimate 
STEMI   ST-segment elevation myocardial infarction  
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INTRODUCTION 
Prognosis of patients with acute myocardial infarction (AMI) has significantly improved over 
the last decades, primarily as a result of advances in interventional and medical treatment 
options 1. Nevertheless, AMI survivors still face a substantial risk of recurrent, potentially life-
threatening cardiovascular events. Early risk assessment based on clinical characteristics and 
myocardial function is recommended to further reduce morbidity and mortality following AMI 2, 
3
. Left ventricular ejection fraction (LVEF) is a powerful predictor of adverse events and the 
preferred functional marker for routine risk stratification and therapeutic decision making 2-6. 
However, LVEF is mainly determined by global, systolic function while not adequately 
reflecting other components of cardiac contractility or subtle, focal changes. Furthermore, the 
majority of AMI survivors maintain a preserved or only moderately reduced LVEF. 
Consequently, the greatest number of recurrent adverse events occur in these patients despite 
their lower relative risk compared to the high-risk but small group of patients with severely 
impaired LVEF. For these reasons, LVEF has major limitations as a standalone parameter for 
post-infarction outcome and increasing efforts were directed to improve risk stratification 
beyond sole calculation of LVEF 6. Cardiac magnetic resonance (CMR) imaging allows detailed 
visualization of morphological and microvascular alterations after AMI, which provides 
incremental prognostic information over and above established clinical variables and LVEF 4, 
7
. Moreover, CMR myocardial feature tracking (CMR-FT) derived deformation indices emerged 
as a superior measure of left ventricular (LV) performance and a valuable tool for optimized 
post-infarction risk assessment 8, 9. CMR-FT techniques have also been successfully applied 
for quantification of LV dyssynchrony, another potentially useful prognostic marker in patients 
with AMI 10-12. Post-infarction dyssynchrony has been associated with hemodynamic 
alterations, adverse LV remodeling, and clinical outcome 13-19. However, the usefulness of LV 
dyssynchrony for the prediction of future cardiovascular events in AMI survivors has not yet 
been comprehensively evaluated in an adequately sized multicenter trial. The aim of this study 
was, therefore, to determine the prognostic value of CMR-FT based assessment of LV 
dyssynchrony in a large, multicenter AMI population including patients with ST-segment 
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elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction 
(NSTEMI). 
 
MATERIAL AND METHODS 
Study population 
The population of this multicenter CMR study consisted of 1235 patients with AMI participating 
in 2 randomized trials, the AIDA STEMI (Abciximab Intracoronary versus intravenously Drug 
Application in STEMI) and the TATORT NSTEMI (Thrombus Aspiration in Thrombus 
Containing Culprit Lesions in NSTEMI) trial 20-22. Detailed study protocols and main results 
have been published previously. In brief, AIDA STEMI randomly assigned patients presenting 
with STEMI in the first 12 hours after symptom onset to intracoronary or intravenous abciximab 
bolus during primary percutaneous coronary intervention with subsequent 12-h intravenous 
infusion in both groups 20. Consecutive patients at 8 sites in Germany with proven expertise in 
CMR imaging were enrolled in the CMR substudy (n=795) 21. The results did not show a 
difference regarding clinical outcome or CMR parameters of myocardial damage between the 
treatment groups 20, 21. The TATORT NSTEMI trial randomized 440 patients with NSTEMI at 7 
sites in Germany to investigate the effect of aspiration thrombectomy on microvascular 
damage in CMR imaging 22. Compared to standard percutaneous coronary intervention, 
additional aspiration thrombectomy did not improve reperfusion injury, infarct size, or clinical 
outcome. Patients in both studies received reperfusion therapy with primary percutaneous 
coronary intervention and state-of-the-art post-infarction medical treatment according to 
guideline recommendations 2, 3.  
Infarct patients were compared to a control group consisting of 40 consecutive patients who 
underwent CMR imaging within clinical routine at University Medical Center Göttingen. 
Patients were eligible as controls provided that cardiac morphology and function did not show 
any alterations.  
The AIDA STEMI (NCT00712101) and the TATORT NSTEMI trial (NCT01612312) were 
registered with ClinicalTrials.gov and approved by the ethical committees of the participating 
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sites. This CMR-FT study was supported by a grant from the German Center for 
Cardiovascular Research and conducted according to the Declaration of Helsiniki. Patients 
gave written informed consent for study participation.  
CMR imaging protocol 
All patients underwent CMR imaging on clinical 1.5- or 3.0-T scanners within 10 days after 
infarction. The standardized protocol has been previously published and included ECG-gated 
balanced steady-state free precession (b-SSFP) sequences to assess LV function and T1-
weighted late gadolinium enhancement images to determine myocardial and microvascular 
damage 4, 21, 22. All sequences were acquired in 2- and 4-chamber long-axis views as well as 
continuous stacks of short-axis slices covering the whole left ventricle. The same CMR protocol 
was used in all AMI patients and in the control group.  
CMR analysis 
Infarct characteristics and LVEF were analyzed at a core laboratory by blinded investigators 
using certified evaluation software (cmr42, Circle Cardiovascular Imaging Inc, Calgary, Alberta, 
Canada) 4, 21. All parameters were determined in sequential short-axis planes. Established 
threshold techniques were applied to assess infarct size and microvascular obstruction as 
percentage of LV mass.  
CMR-FT was performed in an experienced core laboratory at the University Medical Center 
Göttingen using dedicated software (2D CPA MR, Cardiac Performance Analysis, Version 
1.1.2, TomTec Imaging Systems, Unterschleissheim, Germany). Circumferential and radial 
strain were derived from b-SSFP sequences at basal, midventricular, and apical locations as 
previously described 9, 23. In brief, LV endocardial borders were manually traced followed by 
the application of an automatic border tracking algorithm. Accurate tracking was assured by 
visual review and manual adjustments, if necessary. Final values were based on the average 
of 3 independent analyses. Scans that did not allow for a reliable tracking were excluded. 
Synchrony was evaluated based on the assumption that perfectly synchronous contraction 
results in equal strain across the myocardium at a given point in time, whereas opposing walls 
exhibit opposing strains in dyssynchronous hearts. Therefore, circumferential and radial strain 
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of 48 evenly distributed locations were plotted against spatial positions for each time frame 
within the respective apical, midventricular and basal slices. Corresponding plots were 
subjected to Fourier analysis and circumferential (CURE) and radial uniformity ratio estimates 
(RURE) were calculated per slice with subsequent averaging between spatial locations and 
then expressed as global myocardial values, as previously described 10, 12, 24. Resulting values 
for CURE and RURE range between 0 (corresponding to complete dyssynchrony) and 1 
(corresponding to perfect synchrony). The CMR-FT core laboratory in Göttingen has 
repeatedly proven excellent reproducibility and low inter- and intraobserver variability for strain 
assessments and synchrony analyses 9, 10, 23.  
Clinical endpoints 
The clinical endpoint of this study was the 12-month rate of major adverse cardiac events 
(MACE), consisting of all-cause death, reinfarction, and new congestive heart failure. Each 
patient contributed only once to the composite endpoint to avoid double counting in case of 
multiple events per patient (death > reinfarction > new congestive heart failure). A fully blinded 
clinical endpoints committee adjudicated all events based on data provided by the study sites. 
More detailed endpoint definitions have been reported previously 20-22.  
Statistical analysis 
Categorical variables are presented as frequencies and percentages. Continuous variables 
were non-normally distributed in Shapiro-Wilk test and are provided as median with 
interquartile range (IQR). Comparisons were performed with the chi-square test for categorical 
data and the nonparametric Mann-Whitney U test for continuous variables. Baseline 
characteristics and CMR findings are described according to the occurrence of MACE. 
Furthermore, CURE and RURE were compared to the healthy control group and between 
patients with STEMI and NSTEMI. Patients were stratified according to median dyssynchrony 
estimates to assess the composite 12-month MACE endpoint with the Kaplan-Meier method 
and log-rank testing. Analyses were performed for the overall AMI cohort as well as separately 
for patients with STEMI and NSTEMI. Predictors of MACE were identified in univariate and 
stepwise multivariate Cox regression analyses. Hazard ratios (HR) with corresponding 95% 
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confidence intervals (CI) are provided. All baseline characteristics and CMR findings were 
considered for univariate analysis. Only significant predictors in univariate analysis (p<0.05) 
were included in the multivariate model. The clinical endpoint was also assessed in the 
subgroup of patients with a LVEF >35% using an identical approach. All analyses were 
performed with SPSS version 23.0 (IBM, Armonk, New York, USA). A 2-tailed p-value <0.05 
was considered statistically significant. 
 
RESULTS 
Of the 1235 patients with AMI participating in the AIDA STEMI CMR and the TATORT NSTEMI 
study, 1082 patients had complete CMR protocols with sufficient quality to assess left 
ventricular dyssynchrony (STEMI: n=762; NSTEMI: n=320 / Figure 1). CMR was performed in 
median 3 days (IQR 2 to 4 days) after infarction. Follow-up data 12 months after the index 
event were available in 1080 patients (99.8%) and showed 73 MACE (death: n=32; 
reinfarction: n=21; congestive heart failure: n=20).   
Patient characteristics 
Baseline clinical and angiographic characteristics and their association with MACE are 
illustrated in Table 1. The patient population was predominantly male (75%) with a median age 
of 63 years (IQR 53 to 72 years). Patients with MACE at 12-month follow-up were significantly 
older (p<0.001), less often male (p=0.030) or smokers (p=0.015) and had a higher prevalence 
of hypertension (0.006) and diabetes mellitus (0.006). Furthermore, there were significant 
differences regarding Killip class on admission (p<0.001) and the number of diseased coronary 
vessels (p=0.012). 
CMR infarct characteristics and dyssynchrony estimates 
Structural and functional CMR imaging parameters are provided in Table 2. The median infarct 
size was 13.3% of LV mass (IQR 5.4 to 21.7%) with a microvascular obstruction zone of 0.4% 
of LV mass (IQR 0 to 2.0%) and a LV ejection fraction of 50.5% (IQR 43.5 to 57.6%). Uniformity 
ratio estimates in the overall study population were as follows: CURE 0.84 (IQR 0.75 to 0.89) 
and RURE 0.75 (IQR 0.67 to 0.83). In comparison, a healthy control group [n=40; 50% male; 
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median age 64 years (IQR 46 to 76 years); median LVEF 69% (IQR 65 to 72%)] showed 
significantly higher values for CURE [0.92 (IQR 0.89 to 0.94); p<0.001] and RURE [0.79 (IQR 
0.74 to 0.85); p=0.020]. While CURE was similarly reduced in STEMI and NSTEMI [0.83 (IQR 
0.75 to 0.89) versus 0.84 (IQR 0.76 to 0.89); p=0.544], RURE was significantly lower in STEMI 
patients [0.74 (IQR 0.66 to 0.82) versus 0.78 (IQR 0.68 to 0.84); p=0.001]. Patients with MACE 
had significantly larger infarcts (p=0.001), more microvascular obstruction (p=0.029), a lower 
LVEF (p<0.001) and lower dyssynchrony estimates (p<0.001 for CURE and RURE / Table 2).  
Prognostic value of left ventricular dyssynchrony 
Kaplan-Meier plots showing the risk of MACE according to median CURE and RURE in the 
overall study cohort and in patients with STEMI and NSTEMI are illustrated in Figures 2A and 
2B. Uniformity ratio estimates below median were associated with significantly higher 12-
month event rates in the overall AMI population and in the subgroup of patients with STEMI. 
NSTEMI patients with more pronounced dyssynchrony had numerically more MACE with a 
strong trend towards significance in log-rank testing (p=0.050 for CURE and p=0.067 for 
RURE). In the overall AMI cohort, CURE and RURE were significantly associated with MACE 
in univariate Cox regression analysis (p<0.001 for both) but did not add to the profound 
prognostic implications of age (p=0.002), Killip class (p=0.024) and particularly LVEF (p<0.001) 
in stepwise multivariate testing (Table 3). However, considering only patients with a LVEF 
>35% (n=959), CURE was a significant predictor of MACE (p=0.011) in addition to age 
(p=0.006) and the number of diseased coronary vessels (p=0.015 / Table 4). In contrast, LVEF 
was no longer independently associated with adverse events in this subgroup of AMI patients 
with preserved or only moderately reduced LV function. Kaplan-Meier curves according to 
median dyssynchrony estimates illustrate the prognostic implications of CURE (Figure 3A) 
while RURE was not predictive for MACE in this subgroup of patients (Figure 3B).  
 
DISCUSSION 
The present study is the first to comprehensively assess the prognostic value of LV 
dyssynchrony determined by CMR-FT in a large, multicenter population of patients with AMI. 
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The results indicate a significantly higher 12-month MACE rate in case of ventricular 
dyssynchrony albeit the prognostic implications of LVEF remained superior in the overall study 
population. In patients with a LVEF >35%, however, LV dyssynchrony emerged as an 
independent predictor of post-infarction adverse events. Therefore, estimates of LV 
dyssynchrony enable optimized risk assessment after AMI by expanding and complementing 
the prognostic significance of LVEF, the preferred functional marker in clinical routine.  
Role of CMR for post-infarction risk assessment 
According to current guidelines, it is recommended to determine myocardial function as a key 
prognostic factor in all patients with AMI before hospital discharge 2, 3. Routine 
echocardiography with calculation of LVEF is usually the preferred modality due to its wide and 
easy availability. Nevertheless, CMR imaging allows for a more accurate assessment of LVEF 
and provides additional insights into post-infarction myocardial and microvascular damage. 
Numerous trials have repeatedly shown the incremental prognostic information of infarct size 
and microvascular obstruction beyond established risk factors and thus emphasize the benefits 
of visualizing the structural changes after AMI 4, 7. Furthermore, extended CMR protocols with 
T1 mapping techniques and T2* imaging enable an even more detailed tissue characterization 
with additional value for prognostication in AMI survivors 25-27. Most recently, CMR studies also 
investigated approaches to overcome the drawbacks of sole LVEF calculation for analysis of 
myocardial function and identified CMR-FT as a promising tool. CMR-FT derived 
multidirectional myocardial strain emerged as a superior measure of LV performance and a 
valuable marker for adverse events following AMI over and above LVEF 9. The current CMR-
FT trial focused on LV dyssynchrony, an important aspect of ventricular performance that is 
not sufficiently reflected in LVEF. Mechanical LV dyssynchrony was associated with adverse 
outcome in asymptomatic individuals participating in the Multi-Ethnic Study of Atherosclerosis 
(MESA) and in patients with coronary artery disease 28, 29. Previous studies in AMI cohorts 
mainly targeted the prediction of post-infarction LV remodeling while clinical outcome data are 
sparse and mostly derived from small populations 13-19. Moreover, these investigations used 
different imaging modalities to assess synchronicity (e.g. speckle-tracking echocardiography, 
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single-photon emission computed tomography, or CMR tagging) with known limitations (e.g. 
image quality and observer dependency, radiation exposure, or time consuming acquisition of 
additional CMR sequences). In contrast, CMR-FT-derived dyssynchrony estimates are based 
on high-quality b-SSFP images, which are part of standard CMR protocols. Using this 
innovative technique, our study proves the association between mechanical LV dyssynchrony 
and clinical outcome in AMI survivors with independent prognostic implications in patients with 
a LVEF >35%. The results were driven by significantly higher event rates in STEMI patients 
with dyssynchronous LV contraction. In contrast, the NSTEMI cohort showed a trend without 
reaching statistical significance, which might be due to lesser myocardial damage or the lower 
sample size. With regard to the investigated dyssynchrony estimates, CURE turned out to be 
more suitable for post-infarction risk assessment compared to RURE. This finding is in line 
with previous studies, which identified dyssynchrony measures based on circumferential strain 
as the most robust and reproducible approach 10. Furthermore, the extent of myocardial injury 
might also play a role for the superiority of CURE in the overall population with AMI. CURE is 
already sensitive to subendocardial fibre damage, which can be found in all patients with 
STEMI and NSTEMI. In contrast, RURE responds after more pronounced, transmural 
infarction as usually seen in STEMI patients.  
Clinical implications and future directions 
Currently, LVEF is the only imaging parameter with direct implications for the management of 
post-infarction patients, e.g. in terms of medical treatment or prophylactic cardioverter-
defibrillator implantation. Other functional or morphological CMR parameters have not yet 
found their role in clinical practice despite proven prognostic relevance in multiple studies and 
even superiority to sole LVEF-based risk assessment. There are a few factors that may 
account for this imbalance. First, some clinicians still consider CMR as a complex and time-
consuming examination that is restricted to some highly specialized centers. However, 
contrary to this assumption, local expertise and availability have significantly increased during 
the last decades and a post-infarction CMR protocol can be acquired in roughly 30 minutes, 
which only marginally exceeds the duration of a comprehensive transthoracic 
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echocardiography. Second, the variety of different CMR parameters for risk stratification 
impedes the clinical use and may be confusing for physicians without advanced CMR 
knowledge. Risk-scoring models that incorporate several prognostic markers into a simple 
score have been introduced recently to overcome this drawback 7. The third and probably most 
important reason for the slow implementation of CMR-based risk assessment in clinical routine 
is the lack of studies investigating CMR-guided management approaches in patients with AMI. 
Despite the proven prognostic value of morphological and functional alterations in CMR 
imaging, any benefit of considering these findings for treatment decisions remains speculative 
in the absence of randomized trials. However, the scientific basis to assume improved outcome 
and to initiate such studies is solid. For instance, current decision-making on post-infarction 
primary prophylactic cardioverter-defibrillator implantation, which almost exclusively relies on 
LVEF, is suboptimal. Only a very small portion of patients with implanted devices require 
interventions after AMI and patients with preserved ventricular function are not considered for 
device implantation although arrhythmic events are not uncommon in this population 30. 
Therefore, additional factors, such as LV dyssynchrony, have a great potential to improve post-
infarction arrhythmic risk stratification. Furthermore, LV dyssynchrony might help to prevent 
adverse remodeling after AMI by enabling a more tailored pharmacological therapy (e.g. 
aldosterone antagonists in patients with preserved LVEF but dyssynchronous contraction). 
These and other management approaches deserve further exploration in future studies.  
Limitations 
The population of this multicenter CMR study was recruited at several sites in Germany using 
different CMR vendors. However, the scanning protocol was identical in all centers and data 
analysis was performed centrally in a core laboratory. In the absence of specific 
recommendations regarding the optimal time of CMR imaging after AMI, scans were performed 
within several days after the acute event. It cannot be excluded that CMR-FT parameters may 
change over time due to ongoing remodeling processes, similar to the discussed time-
dependency of myocardial edema 31, 32. Therefore, a later assessment of LV dyssynchrony 
might have resulted in an even better prediction of future cardiovascular events. Furthermore, 
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the results of the present study are restricted to stable AMI patients without contraindications 
to undergo CMR imaging. CMR-FT based assessment of LV dyssynchrony was not compared 
to other techniques (e.g. CMR tagging or displacement encoding with stimulated echoes) and, 
finally, reproducibility of CMR-FT analyses in our core laboratory has been reported in several 
previous publications and was not repeated in the present study 9, 10, 23.  
 
CONCLUSIONS 
This large, multicenter study suggests that CMR-FT based assessment of LV dyssynchrony is 
a novel marker for optimized risk assessment after AMI and provides incremental prognostic 
information particularly in post-infarction patients with preserved or only moderately reduced 
LVEF. 
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Table 1 Baseline characteristics 
Variable All patients (n=1082) 
MACE 
(n=73) 
No MACE 
(n=1007) p 
Age (years) 63 (53, 72) 72 (61, 77) 63 (52, 72) <0.001 
Male sex 811/1082 (75.0) 47/73 (64.4) 763/1007 (75.8) 0.030 
Cardiovascular risk factors 
Current Smoking 
Hypertension 
Hyperlipoproteinemia 
Diabetes mellitus 
Body mass index (kg/m2) 
 
432/1002 (43.1) 
767/1080 (71.0) 
410/1074 (38.2) 
246/1080 (22.8) 
27.4 (25.0, 30.4) 
 
19/66 (28.8) 
62/73 (84.9) 
25/73 (34.2) 
26/73 (35.6) 
27.0 (25.2, 31.0) 
 
412/934 (44.1) 
703/1005 (70.0) 
384/999 (38.4) 
219/1005 (21.8) 
27.4 (24.9, 30.3) 
 
0.015 
0.006 
0.477 
0.006 
0.899 
Previous myocardial infarction 75/1080 (6.9) 5/73 (6.8) 69/1005 (6.9) 0.996 
Previous PCI 90/1081 (8.3) 5/73 (6.8) 84/1006 (8.3) 0.653 
Previous CABG 20/1081 (1.9) 2/73 (2.7) 18/1006 (1.8) 0.561 
ST-segment elevation 762/1082 (70.4) 51/73 (69.9) 711/1007 (70.6) 0.893 
Time from symptom onset to PCI 
hospital admission* (min) 180 (109, 317) 191 (116, 363) 180 (109, 310) 0.397 
Door-to-balloon time* (min) 30 (22, 42) 28 (24, 40) 30 (22, 42) 0.497 
Killip class on admission 
1 
2 
3 
4 
 
964/1082 (89.1) 
80/1082 (7.4) 
21/1082 (1.9) 
17/1082 (1.6) 
 
49/73 (67.1) 
15/73 (20.5) 
4/73 (5.5) 
5/73 (6.8) 
 
913/1007 (90.7) 
65/1007 (6.5) 
17/1007 (1.7) 
12/1007 (1.2) 
<0.001 
 
 
 
 
Number of diseased vessels 
1 
2 
3 
 
541/1082 (50.0) 
327/1082 (30.2) 
214/1082 (19.8) 
 
26/73 (35.6) 
24/73 (32.9) 
23/73 (32.5) 
 
514/1007 (51.0) 
303/1007 (30.1) 
190/1007 (18.9) 
0.012 
 
 
 
Infarct related artery 
Left anterior descending 
Left circumflex 
Left main 
Right coronary artery 
Bypass graft 
 
443/1082 (40.9) 
218/1082 (20.1) 
6/1082 (0.6) 
408/1082 (37.7) 
7/1082 (0.6) 
 
39/73 (53.4) 
13/73 (17.8) 
1/73 (1.4) 
19/73 (26.0) 
1/73 (1.4) 
 
404/1007 (40.1) 
203/1007 (20.2) 
5/1007 (0.5) 
389/1007 (38.6) 
6/1007 (0.6) 
0.109 
 
 
 
 
 
TIMI flow grade before PCI 
0 
1 
2 
3 
 
550/1082 (50.8) 
121/1082 (11.2) 
216/1082 (20.0) 
195/1082 (18.0) 
 
42/73 (57.5) 
5673 (8.2) 
12/73 (16.4) 
13/73 (17.8) 
 
507/1007 (50.3) 
115/1007 (11.4) 
203/1007 (20.2) 
182/1007 (18.1) 
0.617 
 
 
 
 
TIMI flow grade post PCI 
0 
1 
2 
3 
 
20/1082 (1.8) 
21/1082 (1.9) 
82/1082 (7.6) 
959/1082 (88.6) 
 
1/73 (1.4) 
2/73 (2.7) 
8/73 (11.0) 
62/73 (84.9) 
 
19/1007 (1.9) 
19/1007 (1.9) 
74/1007 (7.3) 
895/1007 (88.9) 
0.650 
 
 
 
 
Concomitant medications 
Aspirin 
Clopidogrel/prasugrel/ticagrelor 
Beta-blocker 
ACE inhibitor/AT-1 antagonist 
Aldosterone antagonist 
Statin 
 
1080/1082 (99.8) 
1082/1082 (100) 
1032/1080 (95.6) 
991/1080 (91.8) 
140/1080 (13.0) 
10321080 (95.6) 
 
73/73 (100) 
73/73 (100) 
71/73 (97.3) 
69/73 (94.5) 
22/73 (30.1) 
70/73 (95.9) 
 
1005/1007 (99.8) 
1007/1007 (100) 
959/1005 (95.4) 
921/1005 (91.6) 
118/1005 (11.7) 
960/1005 (95.5) 
 
0.703 
- 
0.462 
0.386 
<0.001 
0.883 
 
Data presented as n/N (%) or median (IQR). P-values were calculated for the comparison between patients with and without 
MACE 
*only assessed in STEMI patients (n=795) 
CABG = coronary artery bypass graft; MACE = major adverse cardiac event; PCI = percutaneous coronary intervention; TIMI = 
Thromboylsis In Myocardial Infarction 
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 Table 2 Cardiac magnetic resonance imaging results 
Variable All patients MACE No MACE p 
Infarct size (% LV) 13.3 (5.4, 21.7) 20.4 (9.3, 28.9) 13.1 (5.3, 21.3) 0.001 
Microvascular obstruction (% LV) 0.4 (0, 2.0) 1.1 (0, 3.2) 0.3 (0, 1.9) 0.029 
LV ejection fraction (%) 50.5 (43.5, 57.6) 40.0 (33.0, 51.9) 50.9 (44.3, 57.6) <0.001 
LV enddiastolic volume (ml) 143 (116, 171) 145 (122, 170) 143 (116, 171) 0.820 
LV endsystolic volume (ml) 70 (53, 91) 86 (61, 110) 69 (53, 89) 0.001 
CURE 0.84 (0.75, 0.89) 0.76 (0.67, 0.86) 0.84 (0.76, 0.89) <0.001 
RURE 0.75 (0.67, 0.83) 0.69 (0.60, 0.79) 0.76 (0.67, 0.83) <0.001 
 
Data presented as n/N (%) or median (IQR). P-values were calculated for the comparison between patients with and without 
MACE.  
CURE = circumferential uniformity ratio estimate, LV = left ventricular, % LV = percentage of left ventricular mass, MACE = major 
adverse cardiac event, RURE = radial uniformity ratio estimate 
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Table 3 Predictors of MACE in univariate and multivariate Cox regression analysis 
 
Variable 
Univariate Stepwise multivariate 
HR (95% CI) p HR (95% CI) p 
Age 1.05 (1.03-1.07) <0.001 1.04 (1.02-1.07) 0.002 
Male sex 0.59 (0.37-0.96) 0.032 - - 
Current smoking 1.90 (1.12-3.24) 0.018 - - 
Diabetes mellitus 1.93 (1.20-3.12) 0.007 - - 
Hypertension 2.36 (1.24-4.48) 0.009 - - 
Killip class on admission 2.04 (1.61-2.58) <0.001 1.47 (1.05-2.04) 0.024 
Number of diseased vessels 1.51 (1.15-2.00) 0.004 - - 
LV ejection fraction (%) 0.94 (0.92-0.96) <0.001 0.94 (0.92-0.97) <0.001 
Infarct size (% LV) 1.03 (1.01-1.05) <0.001 - - 
Microvascular obstruction (% LV) 1.09 (1.03-1.15) 0.003 - - 
CURE 0.00 (0.00-0.02) <0.001 - - 
RURE 0.02 (0.00-0.15) <0.001 - - 
 
95% CI = confidence interval, CURE = circumferential uniformity ratio estimate, HR = hazard ratio, LV = left ventricular, % LV = 
percentage of left ventricular mass, RURE = radial uniformity ratio estimate 
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Table 4 Predictors of MACE in patients with an ejection fraction >35% 
 
Variable 
Univariate Stepwise multivariate 
HR (95% CI) p HR (95% CI) p 
Age 1.05 (1.02-1.08) <0.001 1.04 (1.01-1.07) 0.006 
Male sex 0.53 (0.30-0.96) 0.035 - - 
Current smoking 2.17 (1.09-4.32) 0.027 - - 
Diabetes mellitus 2.75 (1.55-4.86) 0.001 - - 
Hypertension 2.14 (1.00-4.58) 0.049 - - 
Killip class on admission 1.87 (1.33-2.63) <0.001 - - 
Number of diseased vessels 1.59 (1.13-2.24) 0.009 1.61 (1.10-2.37) 0.015 
LV ejection fraction (%) 0.96 (0.92-0.99) 0.013 - - 
Infarct size (% LV) 1.03 (1.00-1.05) 0.029 - - 
CURE 0.01 (0.00-0.08) <0.001 0.02 (0.00-0.39) 0.011 
 
95% CI = confidence interval, CURE = circumferential uniformity ratio estimate, HR = hazard ratio, LV = left ventricular, % LV = 
percentage of left ventricular mass 
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Figure 1 Study flow chart 
 
 
 
AMI = acute myocardial infarction, CMR = cardiac magnetic resonance, CURE = circumferential uniformity ratio estimate, MACE 
= major adverse cardiac events, NSTEMI = non-ST-segment elevation myocardial infarction, RURE = radial uniformity ratio 
estimate, ST = ST-segment elevation myocardial infarction 
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Figure 2 Kaplan-Meier plots according to median uniformity ratio estimates 
 
 
 
AMI = acute myocardial infarction, CURE = circumferential uniformity ratio estimate, MACE = major adverse cardiac events, 
NSTEMI = non-ST-segment elevation myocardial infarction, RURE = radial uniformity ratio estimate, ST = ST-segment elevation 
myocardial infarction 
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Figure 3 Kaplan-Meier plots according to median uniformity ratio estimates in patients with 
an ejection fraction >35% 
 
 
 
AMI = acute myocardial infarction, CURE = circumferential uniformity ratio estimate, MACE = major adverse cardiac events, 
NSTEMI = non-ST-segment elevation myocardial infarction, RURE = radial uniformity ratio estimate, ST = ST-segment elevation 
myocardial infarction 
 
